Business Wire

KNOWBE4

4.6.2024 14:01:35 CEST | Business Wire | Press release

Share
KnowBe4's Annual Phishing Benchmarking Report Reveals UK & Ireland Outperform Global Average in Cybersecurity Awareness

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today released its new 2024 Phishing by Industry Benchmarking Report to measure an organization’s Phish-prone™ Percentage (PPP), which indicates how many of their employees are likely to fall for phishing or social engineering scams.

This year’s report shows that according to baseline testing done and conducted across industries, in general, British and Irish employees fare better at 32.3% than the worldwide average of 34.3%. This means that, more often than not, employees in the United Kingdom and Ireland (UK&I) are more vigilant in identifying malicious links and other forms of phishing.

KnowBe4 analysed 54 million simulated phishing tests involving nearly 12 million users across 55,675 organisations in 19 different industries, establishing a PPP baseline that reflects the click rates on phishing tests by employees without KnowBe4 security training.

The findings in the report clearly demonstrate the effectiveness of combining simulated phishing security tests with security awareness training. British and Irish organizations that engaged in consistent training and testing experienced a substantial decrease in their average PPP to 18.4% within the first 90 days, and a further reduction to 4.5% after a year of continuous training and testing. This is a significant improvement from the previous year’s results and underscores the value of regular, targeted training.

These results are below the global average of 18.9% after 90 days and 4.6% after one year of consistent training and testing, suggesting that employees in these regions are well informed and more familiar with the tactics of cybercriminals. Despite being a front-runner when compared to the rest of Europe, organisations must continue to focus on mitigating the human risk that exists when safeguarding against cyber threats.

The considerable overall improvement in PPP over three and 12 months is evidence that transforming cybersecurity culture requires breaking existing habits to make way for more secure ones. As employees adopt new behaviours and these become habitual, they evolve into standard practices that shape organisational culture, creating a workforce that instinctively prioritises security.

Some interesting facts highlighted and discussed in the report include:

  • The UK&I region has seen an increase in attacks on organisations of all sizes, particularly on critical national infrastructure, as well as attacks on individuals with access to high-risk information
  • Ransomware continues to be one of the most dominant cyber threats with phishing as its most common attack vector
  • The increased risk of disruptive misinformation and disinformation campaigns due to local elections
  • The severe economic impact of cyber attacks
  • 71% of organisations report that cybersecurity is a high priority for their senior management, but due to tough economic conditions it often falls to the wayside
  • AI is lowering the barrier of entry to novice cybercriminals allowing them to carry out effective attacks

"AI-driven threats are bound to increase, targeting individuals through social engineering and spreading disinformation," says Javvad Malik, lead security awareness advocate at KnowBe4. "It’s imperative that organisations continue to mitigate human risk alongside technological defences to effectively counter cyber threats. It’s thus encouraging to see a growing trend of organisations in the UK and Ireland starting to move beyond awareness to actively focus on employee behavioural change and establishing strong security cultures."

This year’s report also examines phishing benchmarks from North America, South America, Europe, Africa, Asia, Australia and New Zealand.

To download a copy of the 2024 KnowBe4 Phishing by Industry Benchmarking Report, click here.

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 65,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. The late Kevin Mitnick, who was an internationally recognized cybersecurity specialist and KnowBe4’s Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Organizations rely on KnowBe4 to mobilize their end users as their last line of defense and trust the KnowBe4 platform to strengthen their security culture and reduce human risk.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604964525/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye